{
    "clinical_study": {
        "@rank": "165015", 
        "brief_summary": {
            "textblock": "To define the pharmacokinetic characteristics of Nystatin LF IV (intravenous) in human\n      subjects with AIDS-related complex (ARC) after administration of a single IV dose at each of\n      4 dose levels."
        }, 
        "brief_title": "Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "AIDS-Related Complex"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have the following:\n\n          -  Positive HIV antibody test.\n\n          -  Diagnosis of AIDS-related complex (ARC).\n\n          -  CD4+ cell count between 100 and 300 cells/mm3.\n\n          -  Estimated life expectancy of at least 6 months.\n\n          -  Normal neurological status.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Active opportunistic infection requiring ongoing therapy except patients being\n             treated topically for oral thrush.\n\n        Patients with the following are excluded:\n\n          -  Active opportunistic infection.\n\n          -  Known hypersensitivity to polyene antibiotics.\n\n          -  Unwillingness to sign an informed consent or to be in compliance of protocol\n             requirements.\n\n        Prior Medication:\n\n        Excluded within 72 hours of study entry:\n\n          -  Biologic response modifier agents.\n\n          -  Corticosteroids.\n\n          -  Cytotoxic chemotherapeutic agents.\n\n          -  Potential nephrotoxins.\n\n          -  Potential neutropenic agents.\n\n          -  Rifampin or rifampin derivatives.\n\n          -  Systemic anti-infectives.\n\n          -  Phenytoin or barbiturates (inducers of microsomal enzymes).\n\n          -  All systemic medications.\n\n        Prior Treatment:\n\n        Excluded within 72 hours prior to study entry:\n\n          -  Radiation therapy.\n\n        Active alcohol or drug abuse unless they have been off drugs and/or alcohol for two weeks\n        prior to start of study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001998", 
            "org_study_id": "103A", 
            "secondary_id": "AR-90-01-002"
        }, 
        "intervention": {
            "intervention_name": "Nystatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Nystatin"
        }, 
        "keyword": [
            "Nystatin", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77027"
                }, 
                "name": "Twelve Oaks Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Rios A, Crofoot GE, Lenk R, Hayman A, Rosenblum M, Lopez-Berestein G. A phase 1 single dose safety evaluation and pharmacokinetic (Pkc) study of nystatin-liposomal formulation nystatin-LF i.v. in patients with HIV infection. Int Conf AIDS. 1992 Jul 19-24;8(3):127 (abstract no PuB 7473)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001998"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Argus Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1992"
    }, 
    "geocoordinates": {
        "Twelve Oaks Hosp": "29.76 -95.369"
    }
}